European mitochondrial haplogroups [1–2,17].

<p>European mitochondrial haplogroups [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0188492#pone.0188492.ref001" target="_blank">1</a>–<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0188492#pone.0188492.ref002" target="_blank">2</a>,<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0188492#pone.0188492.ref017" target="_blank">17</a>].</p

Associations between haplogroup clusters and univariable clinicopathological data.

<p>Associations between haplogroup clusters and univariable clinicopathological data.</p

Patient characteristics according to haplogroups and haplogroup clusters.

<p>Patient characteristics according to haplogroups and haplogroup clusters.</p

The frequencies and distribution of mtDNA haplogroups in the rheumatoid arthritis patient cohort and two control cohorts from the Danish background population.

<p>The frequencies and distribution of mtDNA haplogroups in the rheumatoid arthritis patient cohort and two control cohorts from the Danish background population.</p

Multivariable analysis of associations between clinicopathological factors and allocation to biological treatment.

<p>Multivariable analysis of associations between clinicopathological factors and allocation to biological treatment.</p

Odds ratio for association between polymorphisms in <i>IL18</i>, <i>NLRP3</i>, <i>TLR1</i> and <i>TLR5</i> and EULAR good/moderate vs. none and good vs. moderate/non-response, respectively.

<p>For <i>TLR5</i> rs5744174, patients were also stratified on diagnosis based on IgM-RF (seropositive-/seronegative RA). Log scale, 95% confidence interval.</p

Linkage disequilibrium-maps for A) <i>NLRP3</i>, B) <i>TLR5</i>, and C) <i>TLR10/1</i>.

<p>Numbers in squares represent r². Darker red indicates stronger linkage disequilibrium. Maps were made using Haploview software version 4.2 and CEPH/CEU HapMap dataset (Phase II+III merged, release 28/ August10). HapMap data were downloaded by respective genes (<i>TLR5</i> and <i>NLRP3</i>) and for <i>TLR10/1</i> data spanning both genes. To simplify LD-maps, SNPs were selected in the following way: NLRP3: minor allele frequency (MAF) >0.1, Hardy-Weinberg equilibrium (HW) p-value >0.01, genotype>50%, force include: rs10754558, force exclude #4–29; TLR5: MAF >0.1, HW p-value >0.01, genotype>50%, force include rs5744176, force exclude # 17–25; TLR10/1: MAF >0.1, HW p-value >0.01, genotype>50%, force include rs11096957, force exclude #4–58, 98–111.</p

Baseline clinical characteristics and treatment response of the study population.

<p>SD: standard deviation; DMARD: disease modifying anti-rheumatic drugs; VAS: visual analogue scale; ΔVAS: baseline VAS minus follow-up VAS; TJC: tender joint count; SJC: swollen joint count; HAQ: health assessment questionnaire; CRP: C-reactive protein; DAS28: disease activity score (28-joints); EULAR: European League Against Rheumatism; ACR50: American College of Rheumatology, 50% improvement; RelDAS28: relative change in DAS28;</p><p>^#: Two-sided t-test p-value of difference in means/proportions between seropositive and seronegative patients; Seropositive: Positive for IgM-RF</p><p>Baseline clinical characteristics and treatment response of the study population.</p

Odds ratio (OR) for association between <i>NLRP3</i> (rs4612666) variant allele and EULAR good/moderate response (log scale, 95% confidence interval).

<p>Patients stratified on diagnose (seropositive-/seronegative RA) or smoking status. Smoking as independent predictor of EULAR good/moderate response: OR = 1.018, p = 0.941.</p

Adjusted odds ratio (OR) for associations between gene variants and ACR50 and relDAS28 response to anti-TNF treatment.

<p>Adj. OR: adjusted odds ratio for ACR50 and coefficient (Coeff.) for relative change in DAS28 (relDAS28). Adjusted for gender, age, HAQ-, DMARD at baseline, CRP, IgM RF status (seropositive/seronegative). Freq.: frequency.</p